The Democratic Republic of the Congo (DRC) has received over 16,000 doses of the Ervebo vaccine as it grapples with its most severe Ebola outbreak to date. This shipment is part of a larger allocation of 70,000 doses promised by the World Health Organization (WHO) and partners. The urgency of this delivery comes as the outbreak has already claimed more than 2,500 lives from nearly 5,300 confirmed cases, with infections spreading at an alarming rate.
While Ervebo is effective against the Zaire strain of Ebola, the current outbreak is caused by the Bundibugyo strain, which lacks an approved vaccine or treatment. However, preliminary animal trial data suggests Ervebo may provide some level of protection. The DRC’s health minister noted that this vaccine has been used extensively in previous outbreaks, including the significant one from 2018 to 2020.
The ongoing outbreak, declared in mid-May, is believed to have started weeks earlier, complicating containment efforts. The WHO warns that transmission rates could triple, exacerbated by armed conflict and inadequate healthcare infrastructure in eastern DRC. As more doses are set to arrive next week, 20,000 will be used in a clinical trial to assess their effectiveness against the Bundibugyo strain.
The situation highlights not only the immediate health crisis but also the broader implications for public health infrastructure in the region. The DRC’s struggle against Ebola underscores the need for robust healthcare systems capable of responding to such outbreaks, especially in conflict-affected areas where access to care is severely limited.
Source: Al Jazeera
